Olmewon H 40 Tablet is a combination antihypertensive medication containing Hydrochlorothiazide 12.5 mg and Olmesartan Medoxomil 40 mg. This formulation is indicated for the treatment of hypertension, helping to lower elevated blood pressure and reduce the risk of cardiovascular events such as stroke and myocardial infarction. Olmesartan Medoxomil, an angiotensin II receptor blocker (ARB), selectively inhibits the binding of angiotensin II to the AT1 receptor, leading to vasodilation and decreased aldosterone secretion, thereby reducing peripheral vascular resistance. Hydrochlorothiazide, a thiazide diuretic, promotes sodium and water excretion by inhibiting sodium reabsorption in the distal convoluted tubules of the kidneys, which decreases plasma volume and contributes to blood pressure reduction. The combination of these two agents provides complementary mechanisms of action, enhancing antihypertensive efficacy while minimizing potential side effects associated with higher doses of individual components. Olmewon H 40 Tablet is typically administered once daily, with dosage adjustments based on patient response and tolerability. It is contraindicated in patients with hypersensitivity to any component, anuria, or severe renal impairment. Regular monitoring of blood pressure, electrolytes, and renal function is recommended during therapy to ensure safety and effectiveness.